Outbreak investigation of Elizabethkingia meningoseptica at a tertiary care hospital

Aim and Objective of the Study: The aim and objective of this study were to do a prospective study on patients with Elizabethkingia meningoseptica infection at AIG Hospitals and to identify the possible source of E. meningoseptica in our hospital. Materials and Methods: Outbreak of infection with E. meningoseptica was identified in intensive care units (ICUs) in February 2021. A prospective study was taken up and environmental surveillance swab cultures were collected along with clinical data from case sheets using a pro forma to identify the possible risk factors associated with E. meningoseptica infection. Interventional strategies were planned by infection control team along with hospital administration. Results: A total of 10 E. meningoseptica bacteraemia and pneumonia cases were documented between March 2021 and May 2021. It was more common among patients with COVID-19, with prolonged ICU stay, and on multiple antibiotics and was associated with poor outcomes. Surveillance swab cultures collected from various sources showed growth of E. meningoseptica in the tap water of some ICUs. Conclusion: Considering that E. meningoseptica are usually resistant to multiple antibiotics and that inappropriate antimicrobial therapy is an independent risk factor for mortality, early diagnosis and adequate antibiotic treatment are vital for patients with E. meningoseptica infection.

[1]  R. Lin,et al.  Bad design, bad practices, bad bugs: frustrations in controlling an outbreak of Elizabethkingia meningoseptica in intensive care units. , 2013, The Journal of hospital infection.

[2]  M. Ratnamani,et al.  Elizabethkingia meningoseptica: Emerging nosocomial pathogen in bedside hemodialysis patients , 2013, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[3]  D. O. Garcia,et al.  Nosocomial infections caused by Elizabethkingia meningoseptica: an emergent pathogen , 2013, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[4]  C. Liao,et al.  Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999–2006 , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[5]  C. Chiu,et al.  Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia. , 2010, International journal of antimicrobial agents.

[6]  Roderick C. Jones,et al.  Acute Emergence of Elizabethkingia meningoseptica Infection among Mechanically Ventilated Patients in a Long-Term Acute Care Facility , 2010, Infection Control & Hospital Epidemiology.

[7]  Yee-Chun Chen,et al.  Association between Contaminated Faucets and Colonization or Infection by Nonfermenting Gram-Negative Bacteria in Intensive Care Units in Taiwan , 2009, Journal of Clinical Microbiology.

[8]  C. Chiu,et al.  Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan , 2009, Scandinavian journal of infectious diseases.

[9]  D. Maki,et al.  Intravascular catheter-related infections: advances in diagnosis, prevention, and management. , 2007, The Lancet. Infectious diseases.

[10]  M. Kim,et al.  Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov. , 2005, International journal of systematic and evolutionary microbiology.

[11]  Ronald N. Jones,et al.  Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001) , 2004, Journal of Clinical Microbiology.

[12]  B. Gordts,et al.  Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  P. Nordmann,et al.  Genetic-Biochemical Analysis and Distribution of the Ambler Class A β-Lactamase CME-2, Responsible for Extended-Spectrum Cephalosporin Resistance inChryseobacterium (Flavobacterium)meningosepticum , 2000, Antimicrobial Agents and Chemotherapy.

[14]  H. Hawley,et al.  Vancomycin therapy of bacterial meningitis. , 1973, American journal of diseases of children.